



Approval for Phase 2 Trials of MTBVAC

[Source:TH](#)

Recently, The [Central Drug Standard Control Organisation's \(CDSCO\)](#) has approved the proposal to conduct the **phase II** clinical trial of the [Mycobacterium Tuberculosis](#) (Live Attenuated) Vaccine.

- The **MTBVAC** is the first vaccine against TB derived from a human source to begin clinical trials in adults in India.
- **Bharat Biotech International Limited** in collaboration with **Spanish biotechnology company Biofabri** have started a series of clinical trials to evaluate the safety, immunogenicity, and efficacy of **MTBVAC** in India.
- MTBVAC is being developed for two purposes as a more effective and potentially long-lasting vaccine than [BCG \(Bacillus Calmette and Guérin\)](#) for newborn children, and for the **prevention of TB in adults and adolescents**, for whom there is currently no effective vaccine.
- MTBVAC is the only vaccine against tuberculosis in clinical trials based on a **genetically modified** form of the pathogen isolated from **humans Mycobacterium tuberculosis**.
- **BCG** is an only attenuated variant of the bovine TB pathogen which is older than a hundred years old and has a very limited effect on pulmonary tuberculosis.

[Read more...](#)

PDF Refernece URL: <https://www.drishtias.com/printpdf/approval-for-phase-2-trials-of-mtbvac>